Search Results - "Goemans, B. F."

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia by GOEMANS, B. F, ZWAAN, Ch. M, KASPERS, G. J. L, HEINRICH, M. C, MILLER, M, ZIMMERMANN, M, HARLOW, A, MESHINCHI, S, LOONEN, A. H, HIHLEN, K, REINHARDT, D, CREUTZIG, U

“…Activating mutations in RAS and receptor tyrosine kinases such as KIT and FLT3 are hypothesized to cooperate with chimeric transcription factors in the…”
Get full text

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples by CLOOS, J, GOEMANS, B. F, CREUTZIG, U, SCHUURHUIS, G. J, ZWAAN, Ch. M, KASPERS, G. J. L, HESS, C. J, VAN OOSTVEEN, J. W, WAISFISZ, Q, CORTHALS, S, DE LANGE, D, BOECKX, N, HÄHLEN, K, REINHARDT, D

“…In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem…”
Get full text

Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia by Goemans, B. F., Zwaan, Ch. M., Martinelli, S., Harrell, P., Lange, D., Carta, C., Reinhardt, D., Hählen, K., Creutzig, U., Tartaglia, M., Heinrich, M. C., Kaspers, G. J. L.

Get full text

Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B by Schauwvlieghe, A.F.A.D., Bredius, R.G.M., Verdijk, R.M., Smiers, F.J.W., van der Beek, M.T., Goemans, B.F., Zwaan, C.M., Brüggemann, R.J., Rijnders, B.J.A.

“…•Azole-resistant aspergillosis is an emerging global problem.•CNS infections with azole-resistant Aspergillus have a dismal outcome.•Three patients were…”
Get full text

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia by Goemans, B F, Zwaan, C M, Vijverberg, S J H, Loonen, A H, Creutzig, U, Hählen, K, Reinhardt, D, Gibson, B E S, Cloos, J, Kaspers, G J L

Get full text

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets by Goemans, Bianca F., Zwaan, Christian M., Harlow, Amy, Loonen, Anne H., Gibson, Brenda E.S., Hählen, Karel, Reinhardt, Dirk, Creutzig, Ursula, Heinrich, Michael C., Kaspers, Gertjan J.L.

“…Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI),…”
Get full text

Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO‐DB SHIP consortium by White, Tara, Kaspers, Gertjan, Abrahamsson, Jonas, Arad‐Cohen, Nira, Cianci, Daniela, Fernandez, Jose, Ha, Shau‐Yin, Hasle, Henrik, De Moerloose, Barbara, Zwaan, C. Michel, Goemans, Bianca F.

“…Summary As treatments for second relapsed and refractory first relapsed paediatric AML transition from purely palliative to more commonly curative in nature,…”
Get full text

Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? by Goemans, Bianca F, Tamminga, Rienk Y J, Corbijn, Carin M, Hählen, Karel, Kaspers, Gertjan J L

Get full text

A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia by Goemans, BF, Zwaan, CM, Reinhardt, D, Gibson, BE, Hahlen, K, Kaspers, GJ

“…Anthracyclines are effective in the treatment of leukemia, but their use is limited because of cardiotoxicity. Liposomal daunorubicin (L-DNR) is potentially…”
Get full text